a prospective, randomised, controlled, double-blind phase i-ii clinical trial on the safety of a-part？ gel as adhesion prophylaxis after major abdominal surgery versus non-treated group前瞻性、随机、对照、双盲i ii期临床试验的安全性一部分凝胶作为主要的腹部手术后粘连预防与各组.pdfVIP

Lang et al. BMC Surgery 2010, 10:20 /1471-2482/10/20 S T U D Y P R O T O C O L Open Access Study protocol A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part® Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group †1 †2 1 3 4 4 Reinhold Lang , Petra Baumann , Karl-Walter Jauch , Claudia Schmoor , Christine Weis , Erich Odermatt and Hanns-Peter Knaebel*2 Abstract Background: Postoperative adhesions occur when fibrous strands of internal scar tissue bind anatomical structures to one another. The most common cause of intra-abdominal adhesions is previous intra-abdominal surgical intervention. Up to 74% of intestinal obstructions are caused by post surgical adhesions. Although a variety of methods and agents have been investigated to prevent post surgical adhesions, the problem of peritoneal adhesions remains largely unsolved. Materials serving as an adhesion barrier are much needed. Methods/Design: This is a prospective, randomised, controlled, patient blinded and observer blinded, single centre phase I-II trial, which evaluates the safety of A-Part® Gel as an adhesion prophylaxis after major abdominal wall surgery, in comparison to an untreated control group. 60 patients undergoing an elective median laparotomy without prior abdominal surgery are randomly allocated into two groups of a 1:1- ratio. Safety parameter and primary endpoint of the study is the occurrence of wound healing impairment or peritonitis within 28 (+10) days after surgery. The frequency of anastomotic leakage within 28 days after operation, occurrence of adverse and serious adverse events during hospital stay up to 3 months and the rate of adhes